Change of management at NTG Nordic Transport Group A/S
Company announcement no. 11 – 25 27 November 2025 Change of management at NTG Nordic Transport Group A/S Appointment of new Group CFO NTG announces the appointment of Tinneke Torpe…
La EMA otorga la designación de medicamento huérfano al tratamiento plasmático de Kedrion
La Agencia Europea de Medicamentos (EMA) otorga la designación de medicamento huérfano al tratamiento plasmático de Kedrion para la aceruloplasminemia congénita, un trastorno genético poco frecuente del metabolismo del hierro…
Neuraxpharm and mjn-neuro announce plans to launch EPISERAS®, a digital health solution using an AI-powered wearable device for the early detection of epileptic seizures
A non-invasive, AI-based, wearable earpiece that continuously monitors brain activity to enable the early detection of seizure risk in real time, alerting patients and caregivers minutes before an episode occurs1…
European Medicines Agency (EMA) grants Orphan Drug Designation to Kedrion’s plasma-derived treatment for Congenital Aceruloplasminemia, a rare genetic disorder of iron metabolism
This designation marks a significant milestone for patients and reaffirms Kedrion’s commitment to addressing unmet medical needs in rare and ultra-rare diseases , /PRNewswire/ — Kedrion announces that the European…
Zelluna ASA: Disclosure of large shareholding
Reference is made to the stock exchange announcement made by Zelluna ASA (the “Company”) on 3 November 2025 regarding the allocation of 5,500,000 new shares in the Company in a…
71,498 Orion Corporation A shares converted into B shares
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 27 NOVEMBER 2025 at 9.00 EET 71,498 Orion Corporation A shares converted into B…
IASO Bio Announces BLA Approval of Fucaso (Equecabtagene Autoleucel) by the Hong Kong Department of Health for the Treatment of Relapsed or Refractory Multiple Myeloma
, /PRNewswire/ — IASO Biotechnology (“IASO Bio”), a commercial-stage biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of novel cell therapies and biologics for hematologic malignancies and autoimmune…
GC Genome Publishes Blood-Based Colorectal Cancer Screening Study in the American Journal of Gastroenterology
, /PRNewswire/ — GC Genome, a leading clinical genomics and liquid biopsy company, announced that its collaborative study with Professor Byeon, Jeong-Sik’s team at Asan Medical Center has been published…
SK Biopharmaceuticals Expands Radiopharmaceutical Therapy Portfolio with Second In-licensed Candidate from Wisconsin Alumni Research Foundation
New addition strengthens SK Biopharmaceuticals’ radiopharmaceutical therapy portfolio and reinforces its R&D capabilities through global partnerships and value chain integration , /PRNewswire/ — SK Biopharmaceuticals, CO., Ltd., a biotech company…
HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 27, 2025 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies…